22nd Century Group Inc. (XXII) and Codexis Inc. (NASDAQ:CDXS) Comparing side by side

22nd Century Group Inc. (NYSEAMERICAN:XXII) and Codexis Inc. (NASDAQ:CDXS) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
22nd Century Group Inc. 2 11.63 N/A -0.10 0.00
Codexis Inc. 18 14.27 N/A -0.21 0.00

Demonstrates 22nd Century Group Inc. and Codexis Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 represents 22nd Century Group Inc. (NYSEAMERICAN:XXII) and Codexis Inc. (NASDAQ:CDXS)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
22nd Century Group Inc. 0.00% -15.6% -14.3%
Codexis Inc. 0.00% -21.1% -13.5%

Risk & Volatility

22nd Century Group Inc. is 68.00% more volatile than S&P 500 because the stock has a beta of 1.68. Competitively, Codexis Inc. is 106.00% less volatile than S&P 500, because of the -0.06 beta.

Liquidity

9.3 and 8.7 are the respective Current Ratio and a Quick Ratio of 22nd Century Group Inc. Its rival Codexis Inc.’s Current and Quick Ratios are 3.4 and 3.4 respectively. 22nd Century Group Inc. has a better chance of clearing its pay short and long-term debts than Codexis Inc.

Insider & Institutional Ownership

22nd Century Group Inc. and Codexis Inc. has shares owned by institutional investors as follows: 35% and 92.2%. 0.8% are 22nd Century Group Inc.’s share owned by insiders. On the other hand, insiders owned about 3.9% of Codexis Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
22nd Century Group Inc. -15.87% -19.7% -28.7% -31.76% -34.84% -36.14%
Codexis Inc. -1.5% -3.26% -6.08% 3.84% 37.09% 10%

For the past year 22nd Century Group Inc. had bearish trend while Codexis Inc. had bullish trend.

Summary

Codexis Inc. beats on 4 of the 7 factors 22nd Century Group Inc.

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The companyÂ’s products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine. 22nd Century Group, Inc. has a scientific collaboration with the University of Virginia; and a strategic partnership with Anandia Laboratories, Inc. The company was founded in 1998 and is headquartered in Clarence, New York.

Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The companyÂ’s platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also improves the pharmaceuticals companies manufacturing productivity and efficiency, as well as helps in outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. Further, the company develops biocatalysts for use in the fine chemicals market, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.